ALEC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alector Inc (ALEC) is not a strong buy for a beginner, long-term investor at this time. The stock has shown significant price declines recently, insider selling is high, and the company's financial performance is weak with declining revenue. While there is a positive analyst upgrade and a shift in focus to novel therapeutics, the lack of strong proprietary trading signals and the absence of recent positive news or significant catalysts make this stock a hold for now.
The MACD is below zero and negatively contracting, suggesting bearish momentum. RSI is neutral at 48.607, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 1.997), which could act as a short-term floor, but there is no strong bullish signal.
BTIG upgraded the stock to Buy with a $6 price target, citing a shift in focus to novel therapeutics with BBB-shuttle domains, which positions the company as a potential leader in the neurodegeneration space.
Insiders have significantly increased selling activity (612.06% increase in the last month). The company's financials show an 88.50% YoY revenue decline in Q4 2025, and the stock has experienced consistent price declines. No recent news or congress trading data is available to support positive sentiment.
In Q4 2025, revenue dropped by 88.50% YoY to $6.24M. Net income improved but remains negative at -$37.27M, and EPS increased to -0.34. Gross margin remains at 100%, but the overall financial performance is weak.
BTIG upgraded the stock to Buy with a $6 price target, citing a shift in the company's focus to novel therapeutics. However, Morgan Stanley maintains an Underweight rating with a price target of $0.90, reflecting mixed sentiment among analysts.
